Tolerability is the second most common reason people give for choosing one of these drugs over another, after price — and the two get traded off against each other constantly. This study is the largest attempt to check whether the trade-off exists at the severe end, and the answer is that it does not. That is a purchasing-relevant negative, which is the kind this market produces least often. It sits alongside the price comparison in what the tirzepatide premium buys.
What was compared
A new-user, active-comparator cohort study identified adults with type 2 diabetes starting dulaglutide, subcutaneous semaglutide or tirzepatide between January 2019 and August 2024, and built three pairwise comparisons, propensity-matched 1:1 within each [1].
That produced 65,238 matched pairs for semaglutide against dulaglutide, 20,893 for tirzepatide against dulaglutide, and 46,620 for tirzepatide against semaglutide. The primary outcome was a composite of acute pancreatitis, biliary disease, bowel obstruction, gastroparesis and severe constipation.
What it found, which is nothing
The hazard ratio for gastrointestinal events was 0.96 (95% CI 0.87 to 1.06) for semaglutide against dulaglutide, 0.96 (95% CI 0.77 to 1.20) for tirzepatide against dulaglutide, and 1.07 (95% CI 0.90 to 1.26) for tirzepatide against semaglutide.
All three intervals contain 1.0, and contain it with room to spare. The last of those, 1.07, is the number most likely to be misread: a point estimate sitting inside a null interval is not a trend toward harm, it is noise around no difference. The authors’ own conclusion is that the three drugs have similar gastrointestinal safety profiles.
Set against what the two cost
Across the 432 injected semaglutide figures and 394 injected tirzepatide figures recorded here, the median billed rates are $179 and $249 a month — a difference of $70, or $840 over a year. Roster read September 2026.
There are real arguments for paying it. The weight evidence favors tirzepatide, and a seller that publishes its whole dose ladder is worth more than one that does not. What this study removes from the list is the argument that the dearer molecule is easier on you: at the severe end, across 132,751 matched pairs, it is not.
The comparison a buyer can actually make
Since the safety difference is not there to shop on, the variables left are the ones this site measures: what a month costs once the fees are in it, whether the figure survives a dose increase, and whether the seller states either. Those are in what a GLP-1 actually costs and nobody says what happens at a higher dose, and the spread between the cheapest and dearest published figure for the same molecule is wider than the gap between the molecules themselves.